The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
Maren Knoedler
Honoraria - Merck Serono
Other Remuneration - Merck Serono
Andreas Dietz
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Thomas Christoph Gauler
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Viktor Gruenwald
No relevant relationships to disclose
Jan Stoehlmacher
No relevant relationships to disclose
Stephan Knipping
No relevant relationships to disclose
Orlando Guntinas-Lichius
No relevant relationships to disclose
Norbert Frickhofen
No relevant relationships to disclose
Michael Schroeder
No relevant relationships to disclose
Georg Maschmeyer
No relevant relationships to disclose
Volker Rethwisch
No relevant relationships to disclose
Boris Haxel
No relevant relationships to disclose
Ulrich Keilholz
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono; Sanofi
Research Funding - Merck Serono